Blair William & Co. IL Purchases New Position in LifeStance Health Group, Inc. $LFST

Blair William & Co. IL purchased a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 13,487 shares of the company’s stock, valued at approximately $70,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in LFST. DekaBank Deutsche Girozentrale bought a new stake in shares of LifeStance Health Group during the 1st quarter valued at approximately $31,000. Park Edge Advisors LLC bought a new stake in shares of LifeStance Health Group during the 2nd quarter valued at approximately $52,000. Xponance Inc. bought a new stake in shares of LifeStance Health Group during the 1st quarter valued at approximately $69,000. Public Employees Retirement System of Ohio bought a new stake in shares of LifeStance Health Group during the 2nd quarter valued at approximately $70,000. Finally, Kapitalo Investimentos Ltda bought a new stake in shares of LifeStance Health Group during the 1st quarter valued at approximately $87,000. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $5.04 on Monday. The company has a market capitalization of $1.96 billion, a P/E ratio of -100.80 and a beta of 1.17. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.48 and a current ratio of 1.48. The company’s 50 day moving average price is $5.34 and its 200-day moving average price is $5.42.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The firm had revenue of $345.31 million for the quarter, compared to the consensus estimate of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.06) EPS. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Insider Transactions at LifeStance Health Group

In other news, major shareholder Summit Partners L. P sold 8,407,643 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the transaction, the insider owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Darren M. Black sold 8,407,643 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the director owned 33,524,715 shares in the company, valued at $169,970,305.05. This trade represents a 20.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,407,643 shares of company stock worth $103,466,750. Company insiders own 6.60% of the company’s stock.

Analyst Upgrades and Downgrades

LFST has been the topic of several research reports. Wall Street Zen lowered shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of LifeStance Health Group in a report on Wednesday, October 8th. Zacks Research raised shares of LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 7th. BTIG Research assumed coverage on shares of LifeStance Health Group in a report on Friday, July 25th. They set a “buy” rating and a $8.00 target price on the stock. Finally, UBS Group boosted their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.